Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07810244
NA

Moxifloxacin Versus Clindamycin in the Management of Odontogenic Maxillofacial Infectious Processes

Sponsor: Nishtar Medical University

View on ClinicalTrials.gov

Summary

Investigators are conducting a trial to compare moxifloxacin against clindamycin for dental infections that spread to the face and jaw. The study will enroll 60 adults who are being treated as outpatients for localized abscesses or cellulitis. Every patient will first receive minor surgical drainage in the clinic. Following drainage, participants are randomly assigned to take either moxifloxacin (400 mg once daily) or clindamycin (300 mg four times daily) for 5 to 7 days. Investigators primary focus is early pain relief. Investigators will measure the drop in pain scores using a 100 mm visual scale at the day 2-3 follow-up visit. Investigators also plan to track how many patients are fully cured by day 5-7, monitor any side effects, and test the infection samples to see exactly which bacteria are present and how participants respond to both drugs.

Official title: Moxifloxacin Versus Clindamycin in the Management of Odontogenic Maxillofacial Infectious Processes: A Preliminary, Intrahospital, Controlled Clinical Trial

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

60

Start Date

2026-10-01

Completion Date

2027-02-15

Last Updated

2026-10-16

Healthy Volunteers

No

Interventions

DRUG

Clindamycin

Clindamycin 300 mg oral capsule, four times daily.

DRUG

Moxifloxacin (400 mg)

Moxifloxacin 400 mg oral tablet, once daily.

Locations (1)

Nishtar Institute of Dentistry Multan

Multan, Punjab Province, Pakistan